Stockreport
MHRA grants UK patients early access to Akcea Therapeutics' Volanesorsen for FCS [Seeking Alpha]
Last akcea therapeutics, inc earnings: 11/5 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations: ir.akceatx.com/media-investors/press-releases
PDF
MHRA grants UK patients early access to Akcea Therapeutics' Volanesorsen for FCSAkcea Therapeutics (NASDAQ:AKCA)announces that volanesorsen has been granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) by the UK'sMedicines and Healthcare Products Regulatory Agency (MHRA), for the treatment of familial chylomicronaemia syndrome (FCS), a rare genetic lipid disorder.This decision will enable patients to access volanesorsen before the European Commission makes a formal decision for its use in Europe.FCS is a severe, rare disorder characterised by extremely high levels of triglycerides, daily symptoms such as abdominal pain, and the risk of recurrent, potentially fatal, acute pancreatitis.Click to subscribe to real-time analytics on AKCANow read:Meridian Bio restructures into two business units »
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AKCA | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AKCA alerts
AKCA alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKCA alerts
High impacting Akcea Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
AKCA
NEWS
NEWS
- Akcea Announces Upcoming Data Presentations at the 2018 American Society of Hematology Annual Meeting[GlobeNewswire]
- Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions[GlobeNewswire]
- Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions[GlobeNewswire]
- Akcea Therapeutics to Present at Upcoming Investor Conferences[GlobeNewswire]
- Akcea Therapeutics (AKCA) CEO Paula Soteropoulos on Q3 2018 Results - Earnings Call Transcript [Seeking Alpha][Seeking Alpha]
- More
AKCA
SEC Filings
SEC Filings
- 11/28/18 - Form DEF
- 11/23/18 - Form 8-K
- 11/6/18 - Form 10-Q
- AKCA's page on the SEC website
- More